Last reviewed · How we verify

NCT05985291

BurstDR Stimulation for Painful Diabetic Neuropathy

Terminated Last updated 6 November 2025
What this trial tests

trial testing SCS in combination with CMM in Painful Diabetic Neuropathy in 6 participants. Terminated before completion.

Timeline
3 July 2023
Primary endpoint
6 October 2025
6 October 2025

Quick facts

Lead sponsorWake Forest University Health Sciences
StatusTerminated
Study typeOBSERVATIONAL
Enrollment6
Start date3 July 2023
Primary completion6 October 2025
Estimated completion6 October 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Wake Forest University Health Sciences

Who can join

22 and older, any sex, with Painful Diabetic Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to demonstrate treatment outcomes of Painful Diabetic Neuropathy (PDN) patients treated with BurstDRTM Spinal Cord Dorsal Column Stimulator (SCS) along with conservative medical management per standard of care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Painful Diabetic Neuropathy

Currently open trials in the same condition.

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05985291.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing